Your browser doesn't support javascript.
loading
Enhancing type 2 diabetes treatment through digital plans of care - a randomized controlled trial: evaluation of change in patient reported outcome measures.
Heald, Adrian; Roberts, Sarah; Albelda Gimeno, Lucia; White, Alison; Gilingham, Erin; Patel, Reena; Bowden Davies, Kelly; Saboo, Anuj; Gibson, Martin; Abraham, Jonathan.
Affiliation
  • Heald A; Department of Diabetes and Endocrinology, Salford Royal Hospitals NHS Trust, Salford, UK.
  • Roberts S; Division of Diabetes, Endocrinology and Gastroenterology, The University of Manchester, Manchester, UK.
  • Albelda Gimeno L; Healum, London, UK.
  • White A; Healum, London, UK.
  • Gilingham E; Middlewood NHS Primary Care Network, Cheshire, UK.
  • Patel R; Park Lane Surgery, Waters Green Medical Centre, Macclesfield, UK.
  • Bowden Davies K; Spinney Medical Centre, Leicester, UK.
  • Saboo A; Manchester Metropolitan University, Manchester, UK.
  • Gibson M; Healum, London, UK.
  • Abraham J; Department of Diabetes and Endocrinology, Salford Royal Hospitals NHS Trust, Salford, UK.
Expert Rev Endocrinol Metab ; 19(4): 385-391, 2024 Jul.
Article in En | MEDLINE | ID: mdl-38567714
ABSTRACT

BACKGROUND:

We investigated how a personalized care-planning software and linked mobile-app may aid people to self-manage their type 2 diabetes (T2D) more effectively. RESEARCH DESIGN AND

METHODS:

People with T2D and glycated hemoglobin (HbA1c) greater than 58 mmol/mol (7.5%) were randomized to either an intervention group receiving a personalized care plan, or the control group receiving usual care. Quality of life (QoL) was measured for both groups using validated questionnaires and one-on-one interviews with a subset of 12 participants from each group.

RESULTS:

QoL for the active treatment group increased, by their EQ -5D-5 L score increasing on average by 0.046, whereas it decreased for the control group on average by 0.009. The EQ Visual Analogue Score (VAS) of the intervention group also increased by 8.2%, whereas the control group had a reduction in EQ VAS score of 2.8% (p = 0.008 for difference).

CONCLUSION:

In this prospective RCT, the findings point to how the provision of personalized care plans can result in an improvement in individuals' self-rated QoL. This may lead to longer term health benefits.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Diabetes Mellitus, Type 2 / Patient Reported Outcome Measures Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Expert Rev Endocrinol Metab Year: 2024 Document type: Article Country of publication: United kingdom

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Quality of Life / Diabetes Mellitus, Type 2 / Patient Reported Outcome Measures Limits: Adult / Aged / Female / Humans / Male / Middle aged Language: En Journal: Expert Rev Endocrinol Metab Year: 2024 Document type: Article Country of publication: United kingdom